"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
DOSAGE AND ADMINISTRATION
The dosage of Visken ® (pindolol) should be individualized. The recommended initial dose of Visken® (pindolol) is 5 mg b.i.d. alone or in combination with other antihypertensive agents. An antihypertensive response usually occurs within the first week of treatment. Maximal response, however, may take as long as or occasionally longer than 2 weeks. If a satisfactory reduction in blood pressure does not occur within 3-4 weeks, the dose may be adjusted in increments of 10 mg/day at these intervals up to a maximum of 60 mg/day.
Visken ® (pindolol) tablets, USP
White, uncoated, heart-shaped tablets; 5 mg and 10 mg, packages of 100. 5 mg tablets engraved "VISKEN (pindolol) 5'' on one side, and embossed "V'' on other side (NDC 0078-0111-05). 10 mg tablets engraved "VISKEN (pindolol) 10'' on one side, and embossed "V'' on other side (NDC 0078-0073-05).
Store and Dispense
Below 86°F (30°C); tight, light-resistant container.
Manufactured by: Novartis Pharmaceuticals Canada Inc. Dorval (Quebec) Canada H9R 4P5. Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. REV: MAY 2007. FDA Rev date: 10/27/2007This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/13/2008
Additional Visken Information
Visken - User Reviews
Visken User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.